NCT00493623View on ClinicalTrials.gov

BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.

PHASE3CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Osteoporosis
Interventions
DRUG

Placebo

Placebo i.v. single dose

DRUG

ibandronate [Bonviva/Boniva]

3mg i.v. single dose

Trial Locations (27)

13285

Marseille

13385

Marseille

13616

Aix-en-Provence

14033

Caen

31059

Toulouse

33076

Bordeaux

34295

Montpellier

35203

Rennes

38434

Échirolles

42277

Saint-Priest-en-Jarez

44035

Nantes

45000

Orléans

49033

Angers

59037

Lille

59462

Lomme

63003

Clermont-Ferrand

68070

Mulhouse

74136

Bonneville

75181

Paris

75475

Paris

75571

Paris

75651

Paris

75674

Paris

76031

Rouen

80054

Amiens

06401

Cannes

06202

Nice

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00493623 - BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis. | Biotech Hunter | Biotech Hunter